Skip to Content
Merck
CN

EHU226461

MISSION® esiRNA

targeting human ITGA1

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CATCAATTCCCAATGTCACAGAAGTAAAGGAGAACATGACATTTGGATCAACTTTAGTCACCAACCCAAATGGAGGATTTCTGGCTTGTGGGCCCTTATATGCCTATAGATGTGGACATTTGCATTACACAACTGGAATCTGTTCTGACGTCAGCCCCACATTTCAAGTCGTGAATTCCATTGCCCCTGTACAAGAATGCAGCACTCAACTGGACATAGTCATAGTGCTGGATGGTTCCAACAGTATTTACCCATGGGACAGTGTTACAGCTTTTTTAAATGACCTTCTTGAAAGAATGGATATTGGTCC

Ensembl | human accession no.

ENSG00000213949

NCBI accession no.

NM_181501

shipped in

ambient

storage temp.

−20°C

Quality Level

100

General description

MISSION® esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class

12 - Non Combustible Liquids

flash_point_f

Not applicable

flash_point_c

Not applicable

wgk

WGK 1

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
ACNV
QCS

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Jeongsoo Hur et al.
ACS nano, 14(11), 15094-15106 (2020-10-10)
Cell therapy and cellular engineering begin with internalizing synthetic biomolecules and functional nanomaterials into primary cells. Conventionally, electroporation, lipofection, or viral transduction has been used; however, these are limited by their cytotoxicity, low scalability, cost, and/or preparation complexity, especially in

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service